MicroGenDX Press Releases

MicroGenDX, a leader in clinical molecular diagnostics, is launching Rapid H5, a qPCR test designed to detect H5 avian influenza A variants, such as H5N1, the current bird flu strain. Intended for physician use in hospitals, clinics, and other healthcare facilities, the test provides rapid, accurate detection to support patient care, clinical decisions, and H5 influenza case management.

Findings From These Studies Could Save Thousands of Lives Through Better Understanding the Mechanistic Basis of Chronic Wound Infection

Industry-Leading Clinical NGS Test Provider MicroGenDX Has Created a New Patient-Focused Website to Improve Access and Discovery of Its D2C Microbial Diagnostic Products

A new study from UCLA and MicroGenDX shows that bacteria may be one of the factors holding back male fertility

Study shows MicroGenDX approach has the potential to revolutionize the prevention of postoperative infections.